SG Americas Securities LLC purchased a new position in Novo Nordisk A/S (NYSE:NVO) during the 4th quarter, HoldingsChannel reports. The institutional investor purchased 20,869 shares of the company’s stock, valued at approximately $1,120,000.
A number of other large investors have also modified their holdings of the stock. Boston Advisors LLC increased its holdings in Novo Nordisk A/S by 73.2% in the 4th quarter. Boston Advisors LLC now owns 13,165 shares of the company’s stock worth $707,000 after buying an additional 5,565 shares during the period. Lenox Wealth Management Inc. increased its holdings in Novo Nordisk A/S by 17.0% in the 4th quarter. Lenox Wealth Management Inc. now owns 108,143 shares of the company’s stock worth $5,804,000 after buying an additional 15,751 shares during the period. Fisher Asset Management LLC increased its holdings in Novo Nordisk A/S by 4.8% in the 4th quarter. Fisher Asset Management LLC now owns 12,705,477 shares of the company’s stock worth $681,903,000 after buying an additional 580,753 shares during the period. Cim LLC increased its holdings in Novo Nordisk A/S by 4.1% in the 4th quarter. Cim LLC now owns 202,053 shares of the company’s stock worth $10,844,000 after buying an additional 8,020 shares during the period. Finally, TRUE Private Wealth Advisors acquired a new position in Novo Nordisk A/S in the 4th quarter worth approximately $327,000. Institutional investors own 6.16% of the company’s stock.
Several brokerages recently weighed in on NVO. Zacks Investment Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $60.00 price target on the stock in a report on Tuesday, January 2nd. Bank of America upgraded shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Wednesday, December 6th. JPMorgan Chase & Co. upgraded shares of Novo Nordisk A/S from an “underweight” rating to a “neutral” rating in a report on Friday, December 29th. Deutsche Bank reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a research note on Monday, January 8th. Finally, Morgan Stanley raised shares of Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a research note on Friday, December 1st. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $64.00.
The company also recently disclosed a special dividend, which will be paid on Tuesday, April 3rd. Stockholders of record on Monday, March 26th will be paid a dividend of $0.8117 per share. The ex-dividend date of this dividend is Friday, March 23rd. This represents a dividend yield of 0.96%. Novo Nordisk A/S’s payout ratio is 35.34%.
Novo Nordisk A/S announced that its Board of Directors has approved a share repurchase program on Thursday, February 1st that permits the company to buyback outstanding shares. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Shares buyback programs are generally a sign that the company’s board of directors believes its shares are undervalued.
TRADEMARK VIOLATION NOTICE: “SG Americas Securities LLC Takes Position in Novo Nordisk A/S (NVO)” was originally posted by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.themarketsdaily.com/2018/02/14/sg-americas-securities-llc-takes-position-in-novo-nordisk-a-s-nvo.html.
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.